The Effects of Iron on Oxidative Stress and Alzheimer’s Disease Biomarkers in Amyloid-Positive and Negative Elderly Individuals

Clinical Trial Details

The purpose of this study is to investigate differences in iron in the brains of subjects with and without beta-amyloid deposition. Iron is an essential mineral in your body, and beta-amyloid is a protein associated with Alzheimer’s disease. Studies suggest that excess iron in the brain may be involved in processes that lead to Alzheimer's disease. This study will use MRI scans, blood samples, and fluid samples to analyze the relationship between brain iron and proteins related to Alzheimer's disease. Eligible participants will be compensated up to $550 for completing 3 baseline procedures and up to $1100 for participating in the entire study. Additional details will be discussed with the study team.

Key Eligibility:

Open to people between the ages of 55 and 90.
Participants should not have a medical condition that can affect the brain, such as cancer, prior stroke, traumatic brain injury, psychiatric illness requiring medication, etc.
Individuals on blood thinners or who have claustrophobia will also not be able to participate.

Detailed eligibility will be reviewed when you contact the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Jacob Tuchinsky
(646) 962-7895
jat4005@med.cornell.edu

Primary Investigator(s)

Gloria Chia-Yi Chiang, MD

Protocol ID(s)

Weill Cornell Medicine IRB #:

2006022283

Status

Open to Enrollment

Age Group

Adult

Disease

Alzheimer's Disease

Healthy Volunteers